Clinical Trials
6 trialsNCT07398599 2026-04-23
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Second Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT05746325 2026-04-02
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
Mayo Clinic
Phase NA Recruiting
NCT07348965 2026-04-02
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Guangzhou University of Traditional Chinese Medicine
Phase NA Recruiting
NCT06643000 2025-03-06
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Henan Cancer Hospital
Phase NA Recruiting
NCT05257967 2025-02-11
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
British Columbia Cancer Agency
Phase NA Recruiting
NCT04944069 2021-06-29
ATTRACT
Second Affiliated Hospital of Nanchang University
Phase NA Unknown